Alumis (ALMS) to Release Quarterly Earnings on Wednesday

Alumis (NASDAQ:ALMS) is projected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Alumis to post earnings of ($1.40) per share for the quarter.

Alumis Stock Performance

Shares of Alumis stock opened at $5.17 on Monday. The firm’s 50-day simple moving average is $7.11 and its 200-day simple moving average is $9.69. Alumis has a 1 year low of $4.74 and a 1 year high of $13.53.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ALMS. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Baird R W upgraded shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. HC Wainwright cut their target price on shares of Alumis from $26.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Oppenheimer began coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price on the stock. Finally, Robert W. Baird began coverage on shares of Alumis in a research note on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Alumis has a consensus rating of “Buy” and an average target price of $26.57.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.